DAXOR CORP 10-Q Summary: Quarter Ended September 30, 2008
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2008, for DAXOR Corporation, a medical device manufacturer and biotech service provider. The company operates two primary segments: Equipment Sales and Related Services (Blood Volume Analyzer and Volumex kits) and Cryobanking and Related Services (blood and semen storage). A significant portion of the company's financial performance is driven by a third, non-operating segment: Investment Activity, which manages a portfolio of utility stocks and derivatives.
Key Financial Metrics
Revenue and Profitability (Nine Months Ended Sept 30, 2008):
- Total Operating Revenue: $1,428,753 (up 2.0% vs. prior year).
- Operating Loss: $(3,714,775) (improved from $(4,008,967) in 2007).
- Net Income: $15,227,192 (up 107% vs. $7,355,512 in 2007).
- Diluted EPS: $3.43 (vs. $1.60 in 2007).
- Investment Income: Realized gains on securities totaled $18,262,577, and mark-to-market gains on short positions were $1,610,482.
Liquidity and Balance Sheet (Sept 30, 2008):
- Cash and Cash Equivalents: $4,036,181.
- Total Assets: $91,761,470 (down from $102.6M at year-end 2007).
- Investment Portfolio (Available-for-Sale): $66,888,238 fair value (Cost: $42.7M; Net Unrealized Gain: $24.2M).
- Total Liabilities: $38,133,055.
- Stockholders' Equity: $53,628,415.
- Debt: Loans payable of $2,264,318 and Mortgage payable of $440,235.
Cash Flow (Nine Months Ended Sept 30, 2008):
- Operating Cash Flow: Net cash used of $(3,562,824).
- Investing Cash Flow: Net cash provided of $7,404,378 (driven by sales of securities and options).
- Financing Cash Flow: Net cash used of $(1,835,207) (includes dividend payments of $1.08M and treasury stock purchases).
Material Changes vs. Prior Period
- Operating Revenue Growth: Equipment sales revenue increased due to the sale of one Blood Volume Analyzer in Q3 2008 ($65,000) compared to none in Q3 2007. Kit sales volume increased 19.6% in Q3.
- Investment Performance: Net income surged primarily due to a $8.7M increase in realized gains on the sale of securities compared to the prior year. Mark-to-market adjustments on short positions shifted from a loss of $3.25M in Q3 2007 to a loss of only $0.53M in Q3 2008.
- Expense Reduction: Consolidated operating expenses decreased by 4.9% year-over-year, largely due to reduced payroll costs.
- Dividend Policy: The company declared a quarterly dividend of $0.25 per share, a policy not maintained since 1996.
Outlook, Risks, and Management Commentary
Regulatory Risk (CMS Policy Change): A significant risk factor is the Centers for Medicare and Medicaid Services (CMS) policy change effective January 1, 2008. Diagnostic radiopharmaceuticals (Daxor's Volumex) are no longer separately reimbursable by Medicare for outpatient services. Hospitals must now absorb the cost. Management states the impact on future revenue is currently unquantifiable, though industry groups are attempting to reverse the ruling.
Investment Strategy: The company relies heavily on its investment portfolio to offset operating losses. The portfolio is primarily composed of electric utility stocks. The company utilizes covered calls, put options, and limited short sales (up to 15% of portfolio value) to generate income. Management notes that without investment income, the company would face a precarious financial situation due to historical operating losses.
Operational Focus: Management is expanding R&D for renal function testing (GFR) and developing a needle-free delivery device ("Max-200") for Volumex. The company plans to hire regional managers to expand sales efforts.
Contingencies: Two pending legal actions are noted, which management intends to defend vigorously. The company also faces concentration risk with three hospitals accounting for 47.55% of Blood Volume Kit sales.
Key Facts for Investor Verification
- Sustainability of Investment Gains: Verify if the $18.3M in realized gains is a recurring trend or a one-time event, as operating segments remain unprofitable.
- Impact of CMS Ruling: Monitor future quarters for the actual revenue impact of the Medicare reimbursement change on Volumex kit sales.
- Customer Concentration: Assess the risk associated with three hospitals representing nearly 48% of kit sales revenue.
- Dividend Sustainability: Confirm if the new quarterly dividend policy can be maintained given the volatility of investment income and the lack of operating profitability.
- Portfolio Valuation: Review the unrealized gains of $24.2M in the investment portfolio, noting that these are not realized cash until securities are sold.